葡萄糖瘤和葡萄糖瘤综合征:一个更新的评论
Sofia Anelli1, Rossella Mazzilli1, Virginia Zamponi1
1Endocrinology Unit, Department of Clinical and Molecular Medicine, ENETS Excellence Center, Sapienza University of Rome, Sant'Andrea Hospital, Rome, Italy.
Clinical endocrinology
|July 4, 2025
概括
葡萄糖瘤是一种罕见的胰腺神经内分泌瘤,表现为特有的皮疹,体重减轻和糖尿病. 最近的数据显示,早期诊断和对死性迁移性红斑的识别增加,改善了患者的治疗结果.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
背景情况:
- 葡萄糖瘤是一种罕见的,缓慢生长的胰腺神经内分泌瘤.
- 它表现为消亡性迁移性红斑,减肥,糖尿病和贫血.
研究的目的:
- 审查有关葡萄糖瘤临床特征,诊断,治疗和预后的文献.
- 为了在三个不同的时间段中比较这些方面.
主要方法:
- 关于葡萄糖瘤病例的文献综述.
- 对1998年之前,1999-2016年和2017年之后发表的研究数据进行比较.
- 分析了最近的86个病例 (2017-2024年).
主要成果:
- 最近的病例 (2017-2024) 显示平均年龄为48.2岁.
- 在93.2%的患者中观察到死亡性迁移性红疹 (NME),在70.3%的患者中观察到糖尿病,在62.2%的患者中观察到体重减轻,在44.6%的患者中观察到贫血.
- 转移发生在52.3%的患者中;瘤的平均长度为4.6厘米,通常在胰腺尾部.
结论:
- 葡萄糖瘤的诊断发生在较早的年龄.
- 越来越多地识别NME表明诊断准确度有所提高.
- 及时诊断对于改善患者预后至关重要.
相关概念视频
Hypoglycemia and Glucagon
349
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
349
Glucagon-like Receptor Agonists
431
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
431
Hormones Regulating Blood Glucose
4.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
4.1K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.4K
Diabetes Mellitus: Overview and Type I Subtype
3.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones
309
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
309


